An Open-Label, Multi-Centre Study of Lapatinib in Combination With Chemotherapy in Patients With ErbB2 Overexpressing Breast Cancer After Trastuzumab Failure in the Neoadjuvant or Adjuvant Setting.

Trial Profile

An Open-Label, Multi-Centre Study of Lapatinib in Combination With Chemotherapy in Patients With ErbB2 Overexpressing Breast Cancer After Trastuzumab Failure in the Neoadjuvant or Adjuvant Setting.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2012

At a glance

  • Drugs Capecitabine; Docetaxel; Lapatinib; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jun 2010 Additional trial identifier (22059) identified as reported by ClinicalTrials.gov.
    • 01 Jun 2010 Actual patient number (9) added as reported by ClinicalTrials.gov.
    • 01 Jun 2010 Planned end date changed from 1 Oct 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top